This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
ABIOMED (ABMD) expects to have gained from its flagship Impella product line in fiscal Q2.
What's in the Offing for Stryker's (SYK) Earnings in Q3?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat third quarter 2019 view are likely to have contributed to Stryker's (SYK) Q3 earnings.
McKesson (MCK) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) Pharmaceutical and Specialty Solutions unit is expected to have driven its fiscal Q2 results.
Can Global Industrial Unit Drive Ecolab's (ECL) Q3 Earnings?
by Zacks Equity Research
Positive developments in the Global Industrial unit are expected to have driven Ecolab's (ECL) Q3 results.
Is Deep Value ETF (DVP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVP
Q3 Earnings Reports to Flood Wall Street This Week
by Zacks Equity Research
Q3 Earnings Reports to Flood Wall Street This Week
Opioid Settlement, Boeing Downgrades: Markets Looking Up
by Mark Vickery
Futures are up somewhat in this Monday's pre-market after a sell-off Friday. Much of the sentiment going forward will rely on Q3 results and other news items.
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Top-line growth, expected increase in bookings and solid show by Population Health, Revenue Cycle and IT Works are anticipated to get reflected in Cerner's (CERN) Q3 earnings.
What's in the Offing for Baxter's (BAX) Earnings in Q3?
by Zacks Equity Research
Baxter's (BAX) Q3 earnings is likely to have benefited from better-than-expected performance at Acute Therapies segment, solid product portfolio and anticipated rise in revenues.
What's in Store for Varian Medical (VAR) in Q4 Earnings?
by Zacks Equity Research
Varian (VAR) is expected to have gained from core Proton Therapy platform in fiscal Q4.
What's in Store for Intuitive Surgical (ISRG) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at Instruments & Accessories segment and da Vinci procedure growth are likely to aided Intuitive Surgical (ISRG) in Q3 earnings.
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dental Supplies Industry's Near-Term Outlook Looks Bright
by Sreyoshi Mukherjee
With popular trends of digital dentistry and robotics gaining momentum, near-term prospects of the dental industry look promising.
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
The Zacks Analyst Blog Highlights: Apple, Exxon, AT&T, Cardinal and ANSYS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Exxon, AT&T, Cardinal and ANSYS
Top Stock Reports for Apple, Exxon Mobil & AT&T
by Mark Vickery
. Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Exxon Mobil (XOM) and AT&T (T).
Why Is Cardinal (CAH) Up 3.5% Since Last Earnings Report?
by Zacks Equity Research
Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Can Value Investors Consider Cardinal Health (CAH) Stock?
by Zacks Equity Research
Let's see if Cardinal Health (CAH) stock is a good choice for value-oriented investors right now from multiple angles.
Company News For Aug 9, 2019
by Zacks Equity Research
Companies in the news are: CAH, KTB, NCLH and VIAB
Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.
Cardinal Health (CAH) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 19.35% and 1.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical and Medical segments are likely to aid Cardinal Health's (CAH) in Q4 earnings.
Analysts Estimate Cardinal Health (CAH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Cardinal Health, Builders FirstSource, AmerisourceBergen, AutoNation and Party City
by Zacks Equity Research
Zacks.com featured highlights include: Cardinal Health, Builders FirstSource, AmerisourceBergen, AutoNation and Party City